We are live on
!
Find out more
T
TOBAM Portfolio holdings
AUM
$412M
1-Year Est. Return
18.33%
This Fund
S&P 500
This Quarter
Est. Return
-7.74%
1 Year Est. Return
+18.33%
3 Year Est. Return
+56.05%
5 Year Est. Return
+49%
10 Year Est. Return
+255.15%
AUM
$1.6B
AUM Growth
-$392M
(-20%)
Cap. Flow
-$203M
Cap. Flow
% of AUM
-12.69%
Top 10 Holdings %
Top 10 Hldgs %
25.61%
Holding
503
New
74
Increased
178
Reduced
101
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$24.5M |
| 2 |
Church & Dwight Co
CHD
|
+$19.6M |
| 3 |
Eversource Energy
ES
|
+$18.2M |
| 4 |
Expedia Group
EXPE
|
+$17.6M |
| 5 |
Kimberly-Clark
KMB
|
+$17.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$31.2M |
| 2 |
Conagra Brands
CAG
|
+$27M |
| 3 |
SEE
Sealed Air
SEE
|
+$22.8M |
| 4 |
Eli Lilly
LLY
|
+$22.1M |
| 5 |
Regency Centers
REG
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28% |
| 2 | Consumer Staples | 25.89% |
| 3 | Communication Services | 10.3% |
| 4 | Technology | 7.09% |
| 5 | Materials | 6.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Telus
TU
$15.2B
| $1.99M | 0.12% |
89,588
-29,939
| -25% | -$740K |
|
102
Toronto Dominion Bank
TD
$199B
| $1.99M | 0.12% |
30,352
+23,187
| +324% | +$1.68M |
|
103
Elanco Animal Health
ELAN
$12.2B
| $1.82M | 0.11% |
92,521
-394,530
| -81% | -$9.34M |
|
104
FIVE9
FIVN
$2.49B
| $1.8M | 0.11% |
+19,800
| New | +$2M |
|
105
Meta Platforms (Facebook)
META
$1.57T
| $1.78M | 0.11% |
11,038
+1,498
| +16% | +$289K |
|
106
Travelers Companies
TRV
$77B
| $1.76M | 0.11% |
10,431
+9,294
| +817% | +$1.62M |
|
107
Teladoc Health
TDOC
$1.14B
| $1.74M | 0.11% |
52,311
-40,261
| -43% | -$1.71M |
|
|
AGR
108
DELISTED
Avangrid, Inc.
AGR
| $1.72M | 0.11% |
+37,318
| New | +$1.73M |
|
109
Dollar General
DG
$29.4B
| $1.59M | 0.1% |
6,461
+1,026
| +19% | +$240K |
|
110
AT&T
T
$176B
| $1.57M | 0.1% |
74,795
+24,900
| +50% | +$497K |
|
111
Thomson Reuters
TRI
$45.8B
| $1.57M | 0.1% |
14,304
+4,451
| +45% | +$472K |
|
112
Deere & Co
DE
$187B
| $1.47M | 0.09% |
4,906
+4,075
| +490% | +$1.5M |
|
113
Host Hotels & Resorts
HST
$15.1B
| $1.4M | 0.09% |
89,550
-686,269
| -88% | -$13.1M |
|
114
Henry Schein
HSIC
$10B
| $1.38M | 0.09% |
17,947
-5,853
| -25% | -$491K |
|
115
New Oriental
EDU
$9.47B
| $1.36M | 0.09% |
67,005
-29,731
| -31% | -$407K |
|
116
Bristol-Myers Squibb
BMY
$136B
| $1.31M | 0.08% |
17,032
+6,077
| +55% | +$463K |
|
117
Vermilion Energy
VET
$1.96B
| $1.3M | 0.08% |
68,438
-39,360
| -37% | -$820K |
|
118
EQT Corp
EQT
$34.5B
| $1.27M | 0.08% |
+37,077
| New | +$1.53M |
|
119
Canadian Pacific Kansas City
CP
$80.5B
| $1.26M | 0.08% |
18,056
+5,163
| +40% | +$374K |
|
120
Coca-Cola
KO
$379B
| $1.26M | 0.08% |
19,990
+1,258
| +7% | +$79.7K |
|
|
PRMW
121
DELISTED
Primo Water Corporation
PRMW
| $1.23M | 0.08% |
91,867
-8,133
| -8% | -$114K |
|
122
PepsiCo
PEP
$188B
| $1.19M | 0.07% |
7,152
+473
| +7% | +$79.6K |
|
123
Zscaler
ZS
$27.7B
| $1.18M | 0.07% |
7,882
-26,996
| -77% | -$4.77M |
|
124
Canadian National Railway
CNI
$74.6B
| $1.16M | 0.07% |
10,344
-9,366
| -48% | -$1.09M |
|
125
Costco
COST
$406B
| $1.13M | 0.07% |
2,350
+151
| +7% | +$76.6K |
|
Similar funds
EC
WIP
KP
MP
AWP
THCM
PA
HP
TOBAM's Q2 2022 Portfolio in Review
As of Q2 2022, TOBAM held 503 positions worth $1.6B, down 20% from $1.99B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
TOBAM withdrew a net $203M in Q2 2022, closing 74 positions and reducing 101 holdings. Its most notable exit was Novavax, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Consumer Staples and Communication Services.
Against the trend, TOBAM opened a new position in Expedia Group worth $11.8M.
- TOBAM's largest Q2 2022 buy was Expedia Group: 124,451 shares worth $11.8M.
- TOBAM added most to Quest Diagnostics in Q2 2022, an estimated $24.5M increase.
- TOBAM's biggest Q2 2022 reduction was Gilead Sciences, cutting an estimated $31.2M.
- TOBAM fully exited Novavax in Q2 2022, selling an estimated $12.8M.
- TOBAM's ten largest holdings make up 26% of its $1.6B portfolio in Q2 2022.
- TOBAM opened 74 new positions and closed 74 in Q2 2022.
- TOBAM's portfolio value fell 20% quarter-over-quarter to $1.6B.
Based on TOBAM's 13F filing for Q2 2022, filed 2 Aug 2022.